However, even if the expression of EpCAM in prostate cancer is variable, one clinical trial evaluating the safety and efficacy of EpCAM CAR-T cells in patients with EpCAM-positive cancer is ongoing (NCT03013712) [114]. This evidence concerns the gene EPCAM and prostate carcinoma.